Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.
- Primary Purpose
- Anti-Biopharmaceutical Immunization : Prediction and analysis of clinical relevance to minimize the risk in Inflammatory bowel disease (IBD)
- Study Types
- Description of Cohorts
- 184 patients (89 female, 95 male) diagnosed with IBD.
- Informed Consent Given?
- Multi-center Study?